Lisata Therapeutics Inc (LSTA) is not a good buy for a beginner, long-term investor at this time. The lack of positive financial performance, absence of trading signals, and neutral sentiment from hedge funds and insiders suggest limited immediate upside potential. Additionally, there are no recent news catalysts or significant analyst activity to support a buy decision.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 39.168, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 4.485, with resistance at 4.587 and support at 4.382, showing limited price movement.

Positive Catalysts

NULL identified. No recent news or significant trading activity from insiders or hedge funds.

Neutral/Negative Catalysts

Declining financial performance with a YoY drop in net income (-13.81%) and EPS (-16.95%). No recent news or trading signals to indicate a reversal in sentiment or performance.

Financial Performance

In Q3 2025, the company reported no revenue growth (0.00% YoY), a decline in net income to -$4.25M (-13.81% YoY), and a drop in EPS to -0.49 (-16.95% YoY). Gross margin remained unchanged at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available on analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast LSTA stock price to rise

Buy

Hold

Sell

Current: 4.100

Low

Averages

High

Current: 4.100

Low

Averages

High

Brookline

Buy

maintain

$20 -> $32

AI Analysis

2025-07-15

Reason